Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,637 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Muscular Diseases Clear all
Recruiting No phase listed Observational

Study of the Disease Process of Lymphangioleiomyomatosis

NCT00001465
View directory record Official record
Conditions
Lung Disease, Pneumothorax, Tuberous Sclerosis, Lymphangioleiomyomatosis
Interventions
Toshibia Aquilion One CT
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
16 Years to 100 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Not applicable Interventional

Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer

NCT01655745
View directory record Official record
Conditions
Bladder Cancer
Interventions
FDG PET/MR
Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Jul 23, 2026, 6:17 PM EDT
Recruiting Phase 2 Interventional

Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance

NCT05796375
View directory record Official record
Conditions
Non-muscle-invasive Bladder Cancer
Interventions
Cystoscopy, Bladder EpiCheck urine test, Xpert Bladder Cancer Monitor urine test
Procedure · Diagnostic Test
Lead sponsor
White River Junction Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
West Haven, Connecticut • Bay Pines, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function

NCT03920865
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

NCT02180867
View directory record Official record
Conditions
Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Interventions
Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
365
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Not applicable Interventional Results available

Metatarsal Phalangeal Joint Deformity Progression - R01

NCT02616263
View directory record Official record
Conditions
Diabetes Mellitus (DM)
Interventions
Foot exercise, Shoulder exercise
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 1, 2024 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures

NCT01674634
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
XIAFLEX / XIAPEX
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Encinitas, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Jul 23, 2026, 6:17 PM EDT
Not yet recruiting Not applicable Interventional

Optimizing Adaptive Intensive Behavioral Therapy for Obesity During the Transition to Older Adulthood

NCT07446907
View directory record Official record
Conditions
Obesity & Overweight, Sarcopenia
Interventions
High Protein Diet Counceling, Standard Protein Diet Counceling, Protein Supplement, Supervised Exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 3 Interventional

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

NCT05767034
View directory record Official record
Conditions
Polymyalgia Rheumatica
Interventions
Secukinumab 300 mg, Secukinumab 150 mg, Placebo to secukinumab
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 100 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
22
States / cities
Avondale, Arizona • Peoria, Arizona • Phoenix, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Not applicable Interventional

Effects of Inspiratory Muscle Training in Persons With Advanced Multiple Sclerosis

NCT03345199
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Inspiratory Muscle Trainer (IMT)
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Jul 23, 2026, 6:17 PM EDT
Recruiting Phase 2 Interventional

Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury

NCT04460872
View directory record Official record
Conditions
Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injury, Central Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male, Spinal Cord Trauma, Injuries, Spinal Cord, Walking, Difficulty, Gait Disorders, Neurologic, Locomotion Disorder, Neurologic, Wounds and Injuries, Nervous System Diseases, Testosterone Deficiency, Androgen Deficiency, Hormone Deficiency
Interventions
Testosterone Enanthate, Locomotor Training
Drug · Behavioral
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis

NCT00005571
View directory record Official record
Conditions
Dermatomyositis
Interventions
h5G1.1-mAb
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating Patient Reported Outcomes (I-PRO) Study for Multidisciplinary Pain Care

NCT02188667
View directory record Official record
Conditions
Chronic Noncancer Pain
Interventions
Providers of Novel Care, Providers of Usual Care
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
4
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Jul 23, 2026, 6:17 PM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

NCT04530487
View directory record Official record
Conditions
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Malignant Peripheral Nerve Sheath Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Rhabdomyosarcoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide, Fludarabine Phosphate, Lapine T-Lymphocyte Immune Globulin, Melphalan, Mycophenolate Mofetil, Tacrolimus, Thiotepa
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 25 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Jul 23, 2026, 6:17 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

NCT06566092
View directory record Official record
Conditions
Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma, Melanoma, Rhabdomyosarcoma, Ewing Sarcoma
Interventions
LN-145/LN-144
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
6 Months to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Aurora, Colorado • St. Petersburg, Florida • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Not applicable Interventional

Biopsychosocial Factors and Muscle Morphology After a Resistance Exercise

NCT07203430
View directory record Official record
Conditions
Low Back Pain, Chronic
Interventions
45-Degree Roman Chair Exercise
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 4 Interventional

Combining N-of-1 Trials to Assess Fibromyalgia Treatments

NCT00000428
View directory record Official record
Conditions
Fibromyalgia
Interventions
Amitriptyline, Amitriptyline plus Fluoxitine
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
7
States / cities
Brockton, Massachusetts • Fall River, Massachusetts • Framingham, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Jul 23, 2026, 6:17 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Use of a Monitor in ME/CFS

NCT01908036
View directory record Official record
Conditions
Chronic Fatigue Syndrome
Interventions
Not listed
Lead sponsor
New York CFS Association
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Jul 23, 2026, 6:17 PM EDT
Recruiting Not applicable Interventional

Individualized Assessment and Treatment for TMD

NCT04376333
View directory record Official record
Conditions
Temporomandibular Joint Disorders, Orofacial Pain
Interventions
Cognitive-Behavioral Treatment, Individualized Assessment and Treatment Program, Standard Conservative Care
Behavioral · Other
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 6:17 PM EDT
Active, not recruiting Not applicable Interventional

Inspiratory Muscle Training in Obese Breast Cancer Survivors

NCT05193149
View directory record Official record
Conditions
Cancer Survivors, Obesity, Breast Cancer
Interventions
Inspiratory muscle training, Exercise training
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 6:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms

NCT07182058
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder)
Interventions
Transcranial Electrical Stimulation Device
Device
Lead sponsor
U: The Mind Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 23, 2026, 6:17 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Virtual Reality Analgesia In Trauma Rehab

NCT03894592
View directory record Official record
Conditions
Virtual Reality, Musculoskeletal Pain, Opioid Use, Anxiety, Virtual Reality Analgesia, Trauma Injury
Interventions
Virtual reality
Other
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
18 Years to 100 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 1 Interventional

Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection

NCT02852564
View directory record Official record
Conditions
Bladder Cancer
Interventions
Ethacrynic Acid
Drug
Lead sponsor
Eugene Lee, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Jul 23, 2026, 6:17 PM EDT
Terminated Phase 3 Interventional Results available

Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia

NCT02829814
View directory record Official record
Conditions
Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Nervous System Diseases, Neuromuscular Diseases, Rheumatic Diseases, Musculoskeletal Diseases
Interventions
TNX-102 SL Tablet, 2.8 mg, Placebo SL Tablet
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Jul 23, 2026, 6:17 PM EDT